MoonLake Immunotherapeutics (NASDAQ:MLTX) — Market Cap & Net Worth
Market Cap & Net Worth: MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $1.06 Billion ($1.06 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8647 globally and #2482 in its home market, demonstrating a -16.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MoonLake Immunotherapeutics's stock price $12.46 by its total outstanding shares 85061685 (85.06 Million). Also see MoonLake Immunotherapeutics asset portfolio for a full breakdown of the balance sheet.
MoonLake Immunotherapeutics Market Cap History: 2020 to 2026
MoonLake Immunotherapeutics's market capitalization history from 2020 to 2026. Data shows growth from $967.15 Million to $1.06 Billion (2.96% CAGR). Also see how efficiently does MoonLake Immunotherapeutics generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
MoonLake Immunotherapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #248 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #920 of 3165 |
Weight: MoonLake Immunotherapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MoonLake Immunotherapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MoonLake Immunotherapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MoonLake Immunotherapeutics share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MLTX by Market Capitalization
Companies near MoonLake Immunotherapeutics in the global market cap rankings as of September 18, 2026. Review MLTX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to MoonLake Immunotherapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
MoonLake Immunotherapeutics Historical Marketcap From 2020 to 2026
Between 2020 and today, MoonLake Immunotherapeutics's market cap moved from $967.15 Million to $ 1.06 Billion, with a yearly change of 2.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.06 Billion | -5.46% |
| 2025 | $1.12 Billion | -75.66% |
| 2024 | $4.61 Billion | -10.33% |
| 2023 | $5.14 Billion | +475.14% |
| 2022 | $893.15 Million | +6.17% |
| 2021 | $841.26 Million | -13.02% |
| 2020 | $967.15 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of MoonLake Immunotherapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.06 Billion USD |
| MoneyControl | $1.06 Billion USD |
| MarketWatch | $1.06 Billion USD |
| marketcap.company | $1.06 Billion USD |
| Reuters | $1.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more